556 related articles for article (PubMed ID: 22711026)
1. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung.
Harrington NE; Sweeney E; Alav I; Allen F; Moat J; Harrison F
J Vis Exp; 2021 Jan; (167):. PubMed ID: 33554970
[TBL] [Abstract][Full Text] [Related]
4. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
5. Activity of Antibiotics against Pseudomonas aeruginosa in an
Diaz Iglesias Y; Van Bambeke F
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
[No Abstract] [Full Text] [Related]
6. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis.
Aaron SD; Ferris W; Ramotar K; Vandemheen K; Chan F; Saginur R
J Clin Microbiol; 2002 Nov; 40(11):4172-9. PubMed ID: 12409393
[TBL] [Abstract][Full Text] [Related]
7. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
Moriarty TF; Elborn JS; Tunney MM
Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
[No Abstract] [Full Text] [Related]
9. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
10. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
[TBL] [Abstract][Full Text] [Related]
11. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
13. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Sousa AM; Monteiro R; Pereira MO
Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
[TBL] [Abstract][Full Text] [Related]
14. Role of Viscoelasticity in Bacterial Killing by Antimicrobials in Differently Grown
Rozenbaum RT; van der Mei HC; Woudstra W; de Jong ED; Busscher HJ; Sharma PK
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745390
[No Abstract] [Full Text] [Related]
15. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients.
Fricks-Lima J; Hendrickson CM; Allgaier M; Zhuo H; Wiener-Kronish JP; Lynch SV; Yang K
Int J Antimicrob Agents; 2011 Apr; 37(4):309-15. PubMed ID: 21382698
[TBL] [Abstract][Full Text] [Related]
16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
18. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
[TBL] [Abstract][Full Text] [Related]
19. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
Schneider-Futschik EK; Paulin OKA; Hoyer D; Roberts KD; Ziogas J; Baker MA; Karas J; Li J; Velkov T
ACS Infect Dis; 2018 May; 4(5):646-655. PubMed ID: 29566483
[TBL] [Abstract][Full Text] [Related]
20. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
[No Abstract] [Full Text] [Related]
[Next] [New Search]